Pharma’s reputation with patient groups is sliding again thanks to prices and shortages; Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion

Taking stock of the drug industry, from the lab to the medicine chest

April 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Pharma's reputation with patient groups is sliding again thanks to prices and shortages Of more than 2,500 groups queried, 57% reported that the industry maintained an "excellent" or "good" reputation, down from 60%. By Ed Silverman STAT+ | Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion Deciphera markets Qinlock, a drug for patients with advanced gastrointestinal stromal tumors, or GIST, a type of cancer that begins in the digestive system. By Adam Feuerstein STAT+ | Doctors Without Borders challenges pharma by releasing costs for a key clinical trial In a challenge to the industry, Doctors Without Borders revealed the detailed costs of a study it ran for a tuberculosis treatment regimen. By Ed Silverman Dom Smith/STAT STAT+ | New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for myelofibrosis, STAT has learned. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser